Incidence and outcome of cytogenetic subgroups and genetic abnormalities in adult T-ALL
| Cytogenetic/genetic subgroup . | No. of cases (positive/tested)* . | Frequency, percentage . | CR (%) . | 5-year survival, percentage (95% CI) . |
|---|---|---|---|---|
| Cytogenetics attempted | 303/356 | 85 | 287 (95) | 49 (44-55) |
| Successful cytogenetics† | 204/303 | 67 | 194 (95) | 49 (42-56) |
| Failed cytogenetics† | 99/303 | 33 | 93 (94) | 51 (41-61) |
| Abnormal karyotype† | 146/204 | 72 | 138 (95) | 46 (38-55) |
| Normal karyotype† | 58/204 | 28 | 56 (97) | 54 (41-67) |
| SIL-TAL1‡ | 8/62 | 13 | 8 (100) | 50 (15-85) |
| TLX3-BCL11B | 4/62 | 6 | 4 (100) | 75 (32-100) |
| t(10;14)(q24;q11)/TLX1-TRA/D@§ | 21/215 | 10 | 20 (95) | 47 (26-69) |
| t(10;11)(p13;q14-q21)/AF10-CALM | 6/214 | 3 | 6 (100) | 67 (13-100) |
| t(11;14)(p15;q11)/LMO1-TRA/D@‖ | 0/215 | 0 | — | — |
| t(11;14)(p13;q11)/LMO2-TRA/D@ | 4/215 | 2 | 4 (100) | 0 |
| MLL translocations¶ | 3/216 | 1 | 3 (100) | 67 (13-100) |
| CDKN2A deletion** | 28/67 | 42 | 28 (100) | 52 (33-71) |
| NUP214-ABL1 | 2/104 | 2 | 2 (100) | 50 (0-100) |
| NOTCH1 mutation†† | 55/90 | 61 | 54 (98) | 53 (39-67) |
| FBXW7 mutation‡‡ | 16/88 | 18 | 16 (100) | 63 (39-86) |
| del(6q) | 22/204 | 11 | 21 (95) | 46 (25-66) |
| del(9p) | 21/204 | 10 | 21 (100) | 48 (26-69) |
| Abnormality of 11q | 13/204 | 6 | 12 (92) | 39 (12-65) |
| del(13q) | 13/204 | 6 | 13 (100) | 46 (19-73) |
| del(17p) | 10/204 | 5 | 9 (90) | 20 (0-45) |
| Complex karyotype§§ | 17/204 | 8 | 15 (88) | 19 (0-38) |
| Cytogenetic/genetic subgroup . | No. of cases (positive/tested)* . | Frequency, percentage . | CR (%) . | 5-year survival, percentage (95% CI) . |
|---|---|---|---|---|
| Cytogenetics attempted | 303/356 | 85 | 287 (95) | 49 (44-55) |
| Successful cytogenetics† | 204/303 | 67 | 194 (95) | 49 (42-56) |
| Failed cytogenetics† | 99/303 | 33 | 93 (94) | 51 (41-61) |
| Abnormal karyotype† | 146/204 | 72 | 138 (95) | 46 (38-55) |
| Normal karyotype† | 58/204 | 28 | 56 (97) | 54 (41-67) |
| SIL-TAL1‡ | 8/62 | 13 | 8 (100) | 50 (15-85) |
| TLX3-BCL11B | 4/62 | 6 | 4 (100) | 75 (32-100) |
| t(10;14)(q24;q11)/TLX1-TRA/D@§ | 21/215 | 10 | 20 (95) | 47 (26-69) |
| t(10;11)(p13;q14-q21)/AF10-CALM | 6/214 | 3 | 6 (100) | 67 (13-100) |
| t(11;14)(p15;q11)/LMO1-TRA/D@‖ | 0/215 | 0 | — | — |
| t(11;14)(p13;q11)/LMO2-TRA/D@ | 4/215 | 2 | 4 (100) | 0 |
| MLL translocations¶ | 3/216 | 1 | 3 (100) | 67 (13-100) |
| CDKN2A deletion** | 28/67 | 42 | 28 (100) | 52 (33-71) |
| NUP214-ABL1 | 2/104 | 2 | 2 (100) | 50 (0-100) |
| NOTCH1 mutation†† | 55/90 | 61 | 54 (98) | 53 (39-67) |
| FBXW7 mutation‡‡ | 16/88 | 18 | 16 (100) | 63 (39-86) |
| del(6q) | 22/204 | 11 | 21 (95) | 46 (25-66) |
| del(9p) | 21/204 | 10 | 21 (100) | 48 (26-69) |
| Abnormality of 11q | 13/204 | 6 | 12 (92) | 39 (12-65) |
| del(13q) | 13/204 | 6 | 13 (100) | 46 (19-73) |
| del(17p) | 10/204 | 5 | 9 (90) | 20 (0-45) |
| Complex karyotype§§ | 17/204 | 8 | 15 (88) | 19 (0-38) |
— indicates not applicable.
Tested by cytogenetics, FISH, reverse-transcribed polymerase chain reaction, or a combination thereof.
An abnormal karyotype was defined as one with a clonal chromosomal abnormality. In the absence of a clonal abnormality, cases with 20 or more analyzable metaphases were classified as having a normal karyotype whereas those with fewer than 20 cells were classified as having failed cytogenetics. All cases with a normal or abnormal karyotype were classified as having successful cytogenetics.
Includes 2 cases with t(1;14)(p32;q11).
Includes 2 cases with t(7;10)(q34-36;q24).
Includes 2 cases with t(7;11)(q34-36;p13).
Includes 2 cases with t(11;19)(q23;p13.3).
Types of deletion: biallelic (n = 13), monoallelic (n = 10), and both (n = 4).
Includes 2 cases with t(7;9)(q34;q34).
Eleven of 16 patients with a FBXW7 mutation also had a NOTCH1 mutation.
Five or more chromosomal abnormalities in the absence of an established subgroup.